ProteoGenix and Cizzle Biotechnology Announce Successful Development of New Antibodies for Early Lung Cancer Detection
Schiltigheim, France – In a groundbreaking collaboration, ProteoGenix, a leading antibody development contract research organization (CRO), has partnered with Cizzle Biotechnology Holdings PLC, an innovative UK-based diagnostics developer, to develop new antibodies targeting the CIZ1B biomarker. This biomarker is closely associated with early-stage lung cancer and has the potential to significantly improve early detection and patient outcomes.
The partnership between ProteoGenix and Cizzle Biotechnology aims to address the critical need for improved diagnostics in one of the world’s deadliest cancers. According to the National Center for Biotechnology Information, lung cancer is responsible for over 1.6 million deaths each year, with only 16% of cases detected early due to current screening limitations.
Through their successful hybridoma antibody development program, ProteoGenix and Cizzle Biotechnology have made significant progress in the fight against lung cancer. Dr. Allan Syms, Chairman of Cizzle Biotechnology, stated, “The excellent collaboration with ProteoGenix has resulted in the generation of specific antibodies to add to our program to detect the CIZ1B cancer biomarker which we have shown is present at the very earliest stages of lung cancer. Our aim is to improve patient survival rates through early detection when surgical or other therapeutic intervention is possible.”
Philippe Funfrock, CEO of ProteoGenix, added, “Our partnership exemplifies the significant progress that can be made when innovative technologies and shared goals come together in the fight against cancer. We are excited about the potential of this non-invasive test to improve early detection and patient outcomes.”
As this blood test advances toward U.S. clinical trials and aims for rapid commercialization, this collaboration sets a new industry standard in the fight against lung cancer by combining ProteoGenix’s expertise in antibody development with Cizzle’s focus on lung cancer diagnostics.
Cizzle Biotechnology is a leading cancer diagnostic innovation company based in the UK, dedicated to improving early cancer detection and patient care. ProteoGenix is a global leader in antibody and protein discovery, engineering, and bioproduction for the diagnostic and biopharma industry.
For more information about ProteoGenix, please visit www.proteogenix.science. For inquiries, please contact Justine Wanner, PhD, Monoclonal Antibody Services – Account Manager at jwanner@proteogenix.fr or +33 (0) 390 20 54 70.
Reference:
National Center for Biotechnology Information. (2023). Lung Cancer Screening. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537283/https://www.ncbi.nlm.nih.gov/books/NBK537283/
Distributed by Pressat.co.uk
